Tegaserod mimics the neurostimulatory glycan polysialic acid and promotes nervous system repair  by Bushman, J. et al.
lable at ScienceDirect
Neuropharmacology 79 (2014) 456e466Contents lists avaiNeuropharmacology
journal homepage: www.elsevier .com/locate/neuropharmTegaserod mimics the neurostimulatory glycan polysialic acid and
promotes nervous system repairq
J. Bushman a, B. Mishra b, M. Ezra a, S. Gul c, C. Schulze b, S. Chaudhury d, D. Ripoll d,
A. Wallqvist d, J. Kohn a, M. Schachner b, e, *, G. Loers b
a New Jersey Center for Biomaterials, Rutgers University, Piscataway, NJ 08854, USA
b Center for Molecular Neurobiology, University Medical Center Hamburg-Eppendorf, D-20246 Hamburg, Germany
c European ScreeningPort GmbH, Schnackenburgalle 114, D-22525 Hamburg, Germany
d DoD Biotechnology High Performance Computing Software Applications Institute, Telemedicine and Advanced Technology Research Center,
US Army Medical Research and Materiel Command, Fort Detrick, MD 21702, USA
e Keck Center for Collaborative Neurosciences, Rutgers University, Piscataway, NJ 08854, USAa r t i c l e i n f o
Article history:
Received 18 April 2013
Received in revised form
30 August 2013
Accepted 11 September 2013
Keywords:
Polysialic acid
Tegaserod
Mimetic
Peripheral nerve
Regeneration
Glycan
Drug repurposingAbbreviations: CDR, complementary determini
granule neuron; DRG, dorsal root ganglion; ELISA, en
assay; FBA, foot base angle; GMP, good manufacturin
HRP, horse radish peroxidase; L, light chain; NCAM, n
NIH, National Institutes of Health; PBS, phosphate buff
L-lysine; PLO, poly-L-ornithine; PLR, protraction limb r
system; PSA, polysialic acid; RI, recovery index; SPR, s
HT, serotonin (5-hydroxytryptamine).
q This is an open-access article distributed unde
Commons Attribution License, which permits unres
reproduction in any medium, provided the original au
* Corresponding author. Department of Cell Biolog
The State University of New Jersey, Nelson Labs D251,
NJ 08854-6999, USA. Tel.: þ1 732 445 1780; fax: þ1 7
E-mail address: schachner@biology.rutgers.edu (M
0028-3908/$ e see front matter  2013 Published by
http://dx.doi.org/10.1016/j.neuropharm.2013.09.014a b s t r a c t
Glycans attached to the cell surface via proteins or lipids or exposed in the extracellular matrix affect
many cellular processes, including neuritogenesis, cell survival and migration, as well as synaptic activity
and plasticity. These functions make glycans attractive molecules for stimulating repair of the injured
nervous system. Yet, glycans are often difﬁcult to synthesize or isolate and have the disadvantage to be
unstable in a complex tissue environment. To circumvent these issues, we have screened a library of
small organic compounds to search for structural and functional mimetics of the neurostimulatory glycan
polysialic acid (PSA) and identiﬁed the 5-HT4 receptor agonist tegaserod as a PSA mimetic. The PSA
mimicking activity of tegaserod was shown in cultures of central and peripheral nervous system cells of
the mouse and found to be independent of its described function as a serotonin (5-HT4) receptor agonist.
In an in vivo model for peripheral nerve regeneration, mice receiving tegaserod at the site of injury
showed enhanced recovery compared to control mice receiving vehicle control as evidenced by func-
tional measurements and histology. These data indicate that tegaserod could be repurposed for treat-
ment of nervous system injuries and underscores the potential of using small molecules as mimetics of
neurostimulatory glycans.
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Elsevier Ltd.1. Introduction
Polysialic acid (PSA) is a homopolymer of a-(2,8)-linked sialic
acid residues numbering up to 200 in length, and is attached pre-
dominantly to the neural cell adhesion molecule (NCAM) (Finne
et al., 1983; Muhlenhoff et al., 1996). PSA is expressed in the
developing and adult nervous system of vertebrates, with expres-
sion localized to migrating cells, processes of neurons and glial
cells, synapses and stem cells (Angata and Fukuda, 2010; Durbec
and Cremer, 2001; Roche et al., 1997). PSA has been suggested to
promote cell motility in the nervous system by primarily expanding
the extracellular space due to its large hydration volume (Yang
et al., 1994) and decreasing homophilic interactions of NCAM
(Durbec and Cremer, 2001). PSA also mediates interactions of
NCAMwith heparan sulfate proteoglycans (Storms and Rutishauser,
1998), brain derived neurotrophic factor (Muller et al., 2000), a-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors
(Vaithianathan et al., 2004), N-methyl-D-aspartate receptors
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et al., 2010) and myristoylated alanine-rich C kinase substrate
(Theis et al., 2013).
The cell motility promoting effects of PSA are of interest for the
treatment of nervous system injuries and disorders. Viral-induced
expression of PSA enhances regeneration after spinal cord injury,
promotes sensory neuron integration into the injured spinal cord,
and increases Purkinje cell dendrite formation following injury
(Zhang et al., 2007a, 2007b, 2007c). Overexpression of PSA on as-
trocytes improves axonal extension across spinal cord injuries (El
Maarouf et al., 2006), and transplanted Schwann cells over-
expressing PSA augment repair in both spinal cord (Luo et al., 2011;
Papastefanaki et al., 2007) and peripheral nerve (Jungnickel et al.,
2012). However, continuously expressed PSA slows the rate of
myelination in vivo (El Maarouf et al., 2006; Franceschini et al.,
2004), and high PSA expression correlates with invasiveness and
malignancy of cancers (Petridis et al., 2009; Tanaka et al., 2001),
suggesting that a dose- and time-constrained approach must be
considered.
As PSA is rapidly degraded by sialidases in the complex tissue
environment (Franz et al., 2005; Martini et al., 1994; Nagai et al.,
1989), peptide mimetics of PSA were identiﬁed and shown to act
as true functional counterparts of PSA (Torregrossa et al., 2004).
Linear and cyclic PSA mimetic peptides have improved functional
recovery following peripheral nerve and spinal cord injuries in
mice (Marino et al., 2009; Mehanna et al., 2010, 2009). Small
organic molecule mimetics of PSA offer further advantages for the
development and regulatory approval for therapies. To build upon
previous advances in identifying PSA mimetics and to increase the
translational potential, we have screened a library of small com-
pounds for mimetics of PSA and identiﬁed tegaserod. Tegaserod is a
drug that received clinical approval for treatment of irritable bowel
syndrome and constipation (Muller-Lissner et al., 2001) by stimu-
lating 5-HT4 receptors on enteric neurons (Liu et al., 2005, 2009).
The present study shows that tegaserod has a second and distinct
mechanism of action as a small organic mimetic molecule of PSA.
2. Materials and methods
2.1. Competition ELISA with small organic compounds
To identify small molecule PSA mimetics the NIH Clinical Collection 1 Library
was screened using methods similar to those previously used by our group (Loers
et al., 2013; Torregrossa et al., 2004). Brieﬂy, the PSA mimicking peptide,
NTHTDPYIYPIDC (Mehanna et al., 2009), coupled to catalase was immobilized on the
surface of 384-well plates (3 mg/ml; 25 ml/well; overnight at 4 C). Tenmicromolar of
molecules from the library were incubated with 0.1 mg/ml and 25 ml/well of the PSA-
speciﬁc monoclonal antibody 735 (Frosch et al., 1985) for 1 h at room temperature
and then added to the wells. An HRP-coupled secondary antibody (1:5000 in PBS;
Jackson ImmunoResearch) and ortho-phenylenediamine (0.5 mg/ml, 5 min; Thermo
Scientiﬁc) as HRP substrate were used to assess antibody binding at room temper-
ature. Binding was quantiﬁed using an ELISA reader (490 nm; mQuant, Bio-TEK) and
the software KCjunior (Bio-TEK). The PSA peptide mimetic was used as a positive
control, and experiments were repeated three times to identify true hits.
Following the initial screen, a competition ELISA was performed with varying
doses of tegaserod maleate (Sequoia Research Products Ltd.) and the negative
control compound nitrendipine (Sequoia Research Products Ltd.). The PSA peptide
mimetic coupled to catalase was immobilized, and wells were incubated with
increasing concentrations of tegaserod and nitrendipine, pre-incubated with anti-
body 735 (0.1 mg/ml) for 1 h at room temperature.
2.2. Surface plasmon resonance (SPR)
Binding afﬁnities of organic compounds to the antibody 735 were evaluated in a
competition experiment by SPR measurements carried out on a BIAcore 3000 in-
strument (GE Healthcare Europe GmbH) with sensor chips maintained at 25 C for
all experimental steps (Schulze, 2000). The running buffer was phosphate buffered
saline, pH 7.3 (PBS). PSA mimicking peptide coupled to catalase was covalently
immobilized to CM5 sensor chips (carboxymethyl dextran; GE Healthcare Europe
GmbH) via primary amino groups, using standard coupling protocols (Karlsson et al.,
1991). In brief, the sensor surface was activated by a 7 min pulse of 0.2 M N-ethyl-N-(3-dimethylaminopropyl) carbodiimide and 50 mMN-hydroxysuccinimide. The PSA
mimetic peptide solution (10 nM in 10 mM sodium acetate, pH 5.2) was then
injected for 5e10 min. Ethanolamine (1 M, pH 8.5) was used to block remaining
activated carboxyl groups (1 h). Ligand densities of 100e150 fmol/mm2 were
reached. Immobilized control peptide (10 nM PSA scrambled peptide mimetic
coupled to catalase) was used as a reference surface. Regeneration of the sensor chip
was achieved by injection of 10 mM glycine, pH 2.5, at 10 ml/min (two 30 s pulses).
The data were analyzed using the BIA evaluation 3.0 software. All sensorgrams were
corrected for background and bulk refractive index by subtraction of the reference.
To conﬁrm that tegaserod binds speciﬁcally to antibody 735, a competition
experiment was performed. First, the antibody (10 nM) was pre-incubated for 1 h at
room temperature with different molar concentrations (1, 2, 5, 8, 15 and 30 mM) of
tegaserod or the negative control compound nitrendipine. Then, the antibody/
organic compound solutions were injected (1 ml/min) to the PSA peptide mimetic-
coupled chip and binding was determined over 30 min. The surface of the sensor
chip was subsequently regenerated with 10 mM glycine, pH 2.5, at 10 ml/min (three
30 s pulses).
2.3. Molecular modeling of tegaserod with the PSA-speciﬁc antibody 735
A model of PSA bound to the binding pocket of the antibody 735 was con-
structed using previous information (Evans et al., 1995). The 3-dimensional co-
ordinates for antibody 735were obtained from the Protein Data Bank (PDB id: 1PLG).
A decamer of PSA was built using the program Discovery Studio (Accelrys Inc.) in
helical conformation making approximately 1/2 of a turnwithin 17A (n¼ 6 residues
per turn). Subsequently, we used the program PYMOL (Schrödinger Inc.) to produce
a model of an eight-residue segment of PSA docked onto the antibody 735. The
resulting model was manipulated in PYMOL to reproduce the speciﬁc inter-
molecular contacts between PSA and antibody 735 that had been identiﬁed
(Evans et al., 1995). The PSA conformation and pose was then energy-minimized in
complex with antibody 735 using Molecular Operating Environment (Chemical
Computing Group) to construct the ﬁnal model.
We carried out ligand docking of tegaserod with antibody 735. The crystal
structure of antibody 735 was used for docking by isolating the immunoglobulin
domains corresponding to the variable regions of the heavy and light chain of
antibody 735, followed by hydrogen placement and energy minimization. We used
Schrödinger’s Glide ligand-docking software (Friesner et al., 2004) to manually
construct a 12 A cubic docking grid that included the entire complementary
determining region (CDR) of antibody 735. We prepared tegaserod using Schrö-
dinger’s Ligprep software and carried out docking using Glide in standard precision
mode. The top-ranked ligand pose was selected for further analysis.
2.4. In vitro analysis of neurite/process outgrowth
Primary cultures of cerebellar granule neurons (cGNs), dorsal root ganglion
(DRG) neurons or Schwann cells were prepared from cerebella or dorsal root ganglia
of 7-day-old (P7) C57BL/6J wild type mice as described (Kleene et al., 2001; Loers
et al., 2005; Mehanna et al., 2009) and motoneurons were prepared from C57BL/
6J wild type or NCAM/ 14-day-old (E14) mouse embryos as described (Simova
et al., 2006). In brief, 48-well plates were coated with 0.01% poly-L-lysine (PLL) or
poly-L-ornithine (PLO) overnight at 4 C. Schwann cells, cerebellar neurons, DRG
neurons (PLL) or motoneurons (PLO) were seeded at a density of 1.25  104
(Schwann cells, DRG neurons and motoneurons) or 2.5 104 cells (cGNs) per well in
250 ml of corresponding serum-free culturemedium and compoundswere added 1 h
after seeding. After maintenance for 24 h at 37 C, cells were ﬁxed with 2.5%
glutaraldehyde and stained with 1% methylene blue/toluidine blue in 1% borax.
Morphological quantiﬁcation of neurite or process lengths was performed as
described (Mehanna et al., 2009). Schwann cell processes and neurites of cGNs, DRG
neurons and motoneurons with a length of at least one cell body diameter were
counted and total neurite or process length per cell was determined by counting 50
cells in each of twowells per experiment using an AxioVision system 4.6 (Carl Zeiss).
At least three independent experiments were performed for each culture condition.
2.5. Effects of tegaserod on femoral nerve regeneration
2.5.1. Mice
All experiments were conducted in accordance with the Rutgers Animal Care
and Facilities Committee and the Institutional Animal Care and Use Committee
(IACUC) and every effort was made to minimize animal suffering and the number of
animals used in experiments. C57BL/6J wild type and NCAM/ mice were used for
all experiments and kept under standard laboratory conditions with food and water
supply ad libitum and with an artiﬁcial 12 h light/dark cycle. Twelve-week-old
C57BL/6J mice were subjected to femoral nerve injury as described (Mehanna
et al., 2009), but with tegaserod substituting for the PSA peptide mimetic. Brieﬂy,
Puramatrix hydrogel (BD Biosciences, Franklin Lakes, NJ) contained within a poly-
ethylene conduit was used as the delivery vehicle for tegaserod. Hydrogels with and
without tegaserodwere induced to gel using 2 PBS as the gelation stimulant within
the conduits, which were then sutured into the injured site. Vehicle consisted of the
same hydrogel contained within the conduit, but without tegaserod.
Fig. 1. Tegaserod competes with PSA peptide mimetic for binding to the PSA-speciﬁc antibody 735 (mAb 735). (A) Results from a competition ELISA of the dose-dependent ability of
tegaserod to interfere with binding of the antibody 735 with the PSA peptide mimetic immobilized at the bottom of the wells, *p < 0.05; ***p < 0.0005 (data were compared by one-
way analysis of variance (ANOVA)). (B) Surface plasmon resonance (SPR) proﬁle of the ability of 100 nM of tegaserod to interfere with binding of antibody 735 with the PSA peptide
mimetic covalently immobilized to a CM5 sensor chip. The SPR signal is displayed as resonance versus time where 1000 RU (resonance units) represent a shift in resonance angle of
0.1 corresponding to a change in surface antibody concentration ofw1 ng/mm2. (C) Surface plasmon resonance (SPR) proﬁle of the ability of 0.1, 1, 10, 20 and 30 mM tegaserod or
nitrendipine to interfere with binding of antibody 735 with the PSA peptide mimetic. Only tegaserod interferes with binding of antibody 735 with the PSA peptide mimetic in a
concentration dependent manner.
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The foot base angle (FBA) was measured before surgery and every week
following surgery before the sacriﬁce of animals as described (Mehanna et al., 2009;
Simova et al., 2006). Single frame video motion analysis (Simi Reality Motion Sys-
tems, Simi Sportsplayer) was used to quantify the angle between the beam and the
foot when the toes from the left leg are fully extended.The protraction limb ratio (PLR) was similarly measured using single frame
motion analysis (Irintchev et al., 2005) and is taken as an indicator of voluntary
movement. Mice are suspended by the tail above a pencil and allowed to grasp
the pencil. The PLR is measured by dividing the relative length that the unin-
jured hind leg extends to the pencil by the length that the injured hind limb
extends.
Fig. 2. Structure models of PSA and tegaserod in complex with the surrogate PSA binding pocket of antibody 735 (heavy chain, green; light chain, cyan) derived from molecular
modeling and docking. (A) PSA, depicted in yellow, binds to a broad groove in the antibody 735 CDR region forming multiple hydrogen bonds. (B) Tegaserod, depicted in magenta,
binds within a groove in one region of the putative PSA-binding site, where it is anchored primarily by a salt-bridge formed between the guanidinium group of the ligand with
aspartic acid 105 on the heavy chain located deep within the groove. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of
this article.)
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into account the initial FBA and PLRs of animals before surgery. The recovery index is
calculated in percent by the equation: RI¼ (Xpre Xden)/(Xden Xreinn) 100, where
Xpre, Xden and Xreinn are values prior to operation, during the state of denervation (7
days after injury) and at the end-point of the study (here 42 days after injury),
respectively. An RI value of 100 indicates complete recovery of locomotor function.
2.5.3. Determination of quadriceps muscle mass
At the end of the locomotor measurements, the quadriceps muscles were
removed from the injured and uninjured hind limbs. The muscle was bluntly
dissected starting distally at the level of the patellar tendon, working proximally,
and cut free from its attachments from the patellar tendon distally and from the
pelvis and femur proximally. Muscles were blotted dry using a paper towel and the
mass was weighed using a Mettler Toledo XS105 Dual Range analytical balance.
2.5.4. Histology
Animals were perfused with 4% paraformaldehyde and explanted nerves were
post-ﬁxed in osmium tetroxide and embedded in resin as described (Masand et al.,
2012). One and 2 mm thick cross sections were cut midway into the region of the
regenerated nerve within the conduits, and sections were stained with 1% toluidine
blue and 1% borax. Sections were imaged with a Zeiss Axiocam, using 20, 40, and
100 objectives. ImageJ software was used to calculate the number of axons as
described (Mehanna et al., 2009).3. Results
3.1. Identiﬁcation of tegaserod as potential mimetic of PSA
NIH Clinical Collection 1 Library was screened via competition
ELISA for compounds that inhibit binding of the PSA receptor site of
antibody 735 to a previously identiﬁed peptide mimetic of PSA
(Mehanna et al., 2009). This screen resulted in the identiﬁcation of
six drugs, one of which was tegaserod. To conﬁrm the results of the
initial screen, a second competition ELISA was performed with a
range of tegaserod concentrations. Tegaserod inhibited binding of
antibody 735 to the PSA peptide mimetic in a dose dependent
manner (Fig. 1A), with maximal inhibition at approximately
100 nM. The ability of tegaserod to inhibit binding of the PSA
peptide mimetic to antibody 735 was compared against the control
compound nitrendipine, which did not impede antibody binding at
any concentration.
The capacity of tegaserod to interact with the antibody 735
antigen binding site was also evaluated by surface plasmonresonance (SPR), which provides a more sensitive and kinetic
platform to probe molecular interactions. Tegaserod disrupted
binding of antibody 735 to the PSA peptidemimetic that was bound
to the chip surface by 80% compared to antibody in the absence of
tegaserod (Fig. 1B). Nitrendipine showed markedly less inhibition
than tegaserod. In addition, a concentration dependent inhibition
of binding between antibody 735 and PSA peptide mimetic could
be shown by SPR in the presence of tegaserod, but not in the
presence of the control compound nitrendipine (Fig. 1C).3.2. Molecular modeling of tegaserod in the PSA receptor pocket
To identify how a small molecule such as tegaserod could act as
a mimetic for the larger and negatively charged PSA, molecular
modeling of PSA and tegaserod was performed within the pub-
lished structure for the PSA binding pocket of antibody 735 (Evans
et al., 1995). The broad complementary determining region (CDR) of
antibody 735 contains two biochemically distinct regions: a hy-
drophobic region rich in aromatic residues and several polar resi-
dues, and a positively charged region consisting of multiple lysine
residues. An eight-residue PSA fragment forms a half-helical turn
that binds within a broad cleft in the antibody CDR region (Fig. 2A).
PSA residues 1e4, which expose N-acetyl groups to the antibody
surface bind to the hydrophobic region of the CDR and form
hydrogen bonds with aspartic acid (D)105 e heavy chain (H) and
arginine (R)55 e light chain (L). These interactions are thought to
be critical to the speciﬁcity of antibody 735 for N-acetyl over N-
propyl PSA. By contrast, PSA residues 5e8 present largely nega-
tively charged carboxyl groups to the positively charged region of
the CDR, forming salt-bridges with lysine (K)65-H and K101-H.
Overall, the model conﬁrms previous observations (Evans et al.,
1995), in that the aromatic/polar region of the CDR is responsible
for N-acetyl PSA speciﬁcity, while the positively charged region
forms more promiscuous interactions with multiple negatively
charged groups in PSA.
Using the ligand docking software Glide (Friesner et al., 2004),
tegaserod was docked into the CDR region of antibody 735
without further modiﬁcations to the receptor structure. The top-
ranked pose (Fig. 2B) shows tegaserod binding to the
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with two key residues, D105-L and R55-H, that also mediate PSA
binding. The pose suggests that tegaserod may be further stabi-
lized by cation-V interactions between R55-H and the tegaserod
ring as well as aromatic interactions with numerous residues in
the binding site such as tyrosine (Y)37-L, Y54-L, Y32-H, Y33-H,
and phenylalanine (F)102-H. These docking results suggest that
tegaserod competes with PSA by binding to a hydrophobic groove
within the PSA-binding site of antibody 735 and reproducing a
number of intermolecular hydrogen bonds found in the antibody
735 complex model.
3.3. In vitro activity of tegaserod
Functional activity of tegaserod was assessed in vitro using PSA-
responsive murine cGNs, DRG neurons, Schwann cells, and moto-
neurons. Schwann cells, DRG neurons andmotoneurons are key cell
types involved in peripheral nerve regeneration and muscle re-
innervation and cGNs were chosen because they are, like moto-
neurons and Schwann cells, responsive to PSA, but are known not
to be responsive to serotonin (5-hydroxytryptamine; 5-HT) for
neurite extension (Zilkha-Falb et al., 1997). A doseeresponse curve
of tegaserod for motoneurons, Schwann cells and cGNs, and
revealed that tegaserod affects neurite and process extension of
neurons and Schwann cells, respectively, at 1 nM and reached an
optimal effect at 100 nM for all cell types (Fig. 3A). At doses
exceeding 100 nM, the effects of tegaserod on increasing neurite
and process extension began to decline and reached control levels
between 1 mM and 5 mM.
Experiments were next conducted to compare the activity of
tegaserod with the PSA peptide mimetic and the bacterial PSA
analog colominic acid on motoneuron neurite extension. Colominic
acid, the PSA peptide mimetic, and tegaserod all stimulated neurite
extension of murine motoneurons, while cisapride (another 5-HT4
agonist (Quigley, 2011)) and serotonin did not enhancemotoneuron
neurite extension (Fig. 3B). Furthermore, the 5-HT4 receptor
antagonist GR113808 (Gale et al., 1994) did not inhibit motoneuron
extension and co-treatment of neurons with tegaserod and
GR113808 did not decrease the stimulatory effect of tegaserod.
Importantly, motoneurons isolated from NCAM/ mice were not
enhanced in neurite extension by colominic acid, the PSA peptide
mimetic, or tegaserod, suggesting that tegaserod affects motoneu-
rons via NCAM. Similarly, the effects of tegaserod were comparable
to those of colominic acid and the PSA mimetic peptide on cGNs,
DRGneurons andSchwanncell neurite/process extension (Fig. 3C,D,
E). Neurite/process extension of these cell types could not be
duplicated with serotonin or cisapride, and was not lowered by co-
administration of GR113808 with tegaserod. Finally, exposure to
tegaserod also increased survival ofmotoneurons and cGNs (Fig. 3F).
3.4. Effects of tegaserod on regeneration following femoral nerve
injury
3.4.1. Metrics of functional recovery
The in vivo efﬁcacy of tegaserodwas tested in themouse femoral
nerve injury model, with 250 nM or 2500 nM of tegaserod being
encapsulated in the BD Puramatrix hydrogel within an inert
conduit that was sutured between two nerve stumps with a gap of
2 mm length. The vehicle control group received the same hydrogel
contained within the conduit but without tegaserod. The 2 mm gap
length is sub-critical and limited recovery is expected in the control
group. Locomotor recovery was quantiﬁed as described (Mehanna
et al., 2009) through assessment of the foot base angle (FBA) and
protraction limb ratio (PLR) as shown in Fig. 4. Studies utilizing this
method have found maximal recovery of the FBAs between 75 and85 (Irintchev et al., 2005; Masand et al., 2012; Mehanna et al.,
2009).
3.4.2. Functional recovery
Analysis of the FBA showed that tegaserod improved this
functional metric of regeneration. A sustained improvement of the
FBA in mice receiving 250 nM tegaserod-containing conduits ﬁrst
became apparent 6 weeks after the injury and became statistically
signiﬁcantly different from the vehicle control group at 10 weeks
(Fig. 5A). The level of recovery of the FBA from 250 nM tegaserod
exceeds or is equivalent to the maximal recovery found in other
studies using this model (Irintchev, 2011; Masand et al., 2012;
Mehanna et al., 2009; Simova et al., 2006). Animals that received
the higher dose of tegaserod, 2500 nM, tended toward improved
FBA recovery but did not achieve a statistically signiﬁcant differ-
ence from the vehicle control.
Given the variation between individual animals, a recovery
index (RI) for the FBA was calculated which normalizes the re-
covery at the end of the 15-week assessments to the initial FBA
and the FBA measured at week 1, which is within 5e7 days of the
surgery. The RI is expressed as a percentage, with the vehicle
control group showing an average RI of 37%, with 5 of the 6 ani-
mals clustered between 36% and 42% (Fig. 5B). Animals that had
received 250 nM tegaserod recovered to an average of 62%, while
animals that had received 2500 nM tegaserod showed an RI of
56%, with considerable variation for animals having received
2500 nM tegaserod.
In addition to the FBA measurements, the PLR was evaluated.
Following injury, the injured leg does not extend to the same
extent as the uninjured leg, but will do so as nerve function is
restored (Fig. 4). Analysis of the PRL with and without tegaserod
suggested a positive inﬂuence at a 250 nM tegaserod concentra-
tion, but not at 2500 nM (Fig. 6A). Vehicle control mice without
tegaserod returned to pre-surgery PLR by 8 weeks, compared with
6 weeks for mice having received 250 nM tegaserod. In contrast,
mice that had received 2500 nM tegaserod exhibited PLRs that
remained higher than the other two groups. Calculation of the RI
for each mouse revealed that, although the majority of mice with
2500 nM eventually did recover to an RI of 100%, one mouse
within this group did not recover to pre-surgical PLR functional
performance (Fig. 6B).
3.4.3. Effect of tegaserod treatment on muscle mass
Muscles rapidly atrophy if nerve conduction is lost and will re-
gain muscle mass as reinnervation occurs. The quadriceps muscle,
which is solely innervated by the femoral nerve, wasweighed at the
end of the 15-week recovery period as an additional metric of re-
covery. The quadriceps muscle from the injured limbs of mice that
had received 250 nM tegaserod showed a 50% increase in muscle
mass compared to the quadriceps muscle of the control group
(Fig. 7). Quadriceps muscles from mice having received 2500 nM
tegaserod were slightly heavier when compared to the control
group.
3.4.4. Histological assessment of nerves
At the end of the recovery period, femoral nerves were ﬁxed
and histology was performed to assess the histology of the nerve
1 mm into the 2 mm gap (Fig. 8AeC). Regenerated nerves treated
with vehicle control contained an average of 432 axons,
compared to 589 and 434 for nerves treated with 250 nM and
2500 nM tegaserod, respectively (Fig. 8D). When the degree of
myelination (in percent) and g-ratios of the myelinated axons
were quantiﬁed from images obtained from light miscroscopy, no
signiﬁcant differences between groups were detectable (data not
shown).
Fig. 3. In vitro activity of tegaserod on extension of neurites/processes from and survival of motoneurons, cerebellar granule neurons (cGNs), dorsal root ganglion (DRG) neurons and Schwann cells. (A) Neurite/process extension
following varying doses of tegaserod after 24 h. (B) Comparison of the neurite-extending capabilities of tegaserod and related compounds on murine motoneurons from wild type and NCAM deﬁcient (NCAM/) mice. Tegaserod
elicits neurite extension comparable to the PSA analog colominic acid and the PSA peptide mimetic, which is not observed in motoneurons from NCAM/mice. 5-HT4 agonists serotonin and cisapride as well as the 5-HT4 antagonist
GR113808 do not increase neurite extension from motoneurons, nor did GR113808 attenuate the effects of tegaserod. (CeE) Effects of tegaserod and related compounds on cGNs, DRG neurons and Schwann cells. (F) Relative survival
of motoneurons and cGNs treated with tegaserod and related molecules. Concentrations of compounds, glycans and peptides: tegaserod, serotonin, cisapride and GR113808 (100 nM), colominic acid (3 mM), PSA peptide mimetic
(30 mM). All treatments were performed in duplicates and at least 100 cells were counted for each treatment. Results are from two or more experiments. Mean values  SEM are shown. (CeE) *p < 0.05, **p < 0.005, ***p < 0.0005 via
Student’s t-test.
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Fig. 4. Metrics of functional recovery of limb function following femoral nerve injury.
(AeB) The foot base angle (FBA) is the angle between the walking surface and the hind
foot when the contralateral foot is lifted. (A) In an uninjured mouse, the FBA is 60e70 .
(B) Following injury, the FBA of the injured leg increases to 100e110 . As the femoral
nerve reinnervates the quadriceps muscle and muscle function is restored, the FBA
decreases towards pre-injury levels. (CeD) The protraction limb ratio (PLR) measures
the voluntary movement of the hind limbs to grasp an object when hanging upside
down. The PLR measures the distance between the base of the tail to the tip of the
extended limbs, as measured by dividing the length of the uninjured limb by that of
the injured limb. (C) In uninjured animals, both hind limbs extend equal distances
resulting in a PLR close to 1. (D) Following femoral nerve injury the limb with the
injured nerve fails to extend to the same extent as the uninjured hind limb, giving a
PLR of >1. A decline in the PLR toward 1 over time indicates recovery.
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Drug repurposing has the potential to rapidly introduce new
therapies using existing drugs for novel applications. PreviouslyFig. 5. Evaluation of functional recovery of mice via measurement of the foot base angle (FB
250 nM tegaserod, or 2,500 nM tegaserod. Pre-injury FBAs are between 60 and 70 , which
FBA of mice that received vehicle, 250 nM tegaserod, or 2,500 nM tegaserod over a 15-we
Recovery index (RI) of the FBA of individual animals within each treatment group is shown
*p < 0.05 via one-way ANOVA with Tukey’s post-hoc test.approved drugs have known toxicological and pharmacokinetic
proﬁles and thus have the potential to avoid a repetition of these
time consuming and costly studies prior to gaining approval for a
new application, provided that the therapeutic dose is equal to
or less than the original application. In the majority of cases, a
drug is repurposed for a different indication based on its known
mechanism of action. For example, celecoxib was repurposed from
treating osteoarthritis to familial adenomatous polyposis based on
the activity of inhibiting cyclooxyenase-2 (Phillips et al., 2002).
Other compounds, such as b-lactam antibiotics and minocycline,
have been found to act via thus far undeﬁned molecular mecha-
nisms to upregulate expression of proteins that confer neuro-
protection (Plane et al., 2010; Rothstein et al., 2005). We have, in
contrast to these approaches, used an in vitro approach to investi-
gate new functional mechanisms for a drug targeted to a different
disease paradigm. We have thus been able to present what appears
to be one of the ﬁrst reports on a small molecule mimetic of a
nervous system glycan.
The small organic compound tegaserod was identiﬁed as a PSA
mimetic by a competition ELISA screen and in vitro assays
conﬁrmed its PSA mimicking effect on central and peripheral ner-
vous system cells. Lack of activity on NCAM/ motoneurons and
the inability of serotonin or other 5-HT4 agonists to replicate the
activity of tegaserod in vitro indicate a structural mimicking activity
consistent with the screening method for PSA mimetics and a
functional activity independent of serotonin and/or serotonin re-
ceptors. While the molecular modeling studies and cell culture
assays indicate that tegaserod may act via NCAM and its co-
receptors, it is also conceivable that tegaserod binds to and acts
via additional PSA receptors, such as heparin sulfate proteoglycans
(Storms and Rutishauser, 1998), brain derived neurotrophic factor
(Muller et al., 2000), excitatory amino acid receptors (Hammond
et al., 2006; Kochlamazashvili et al., 2010, 2012; Vaithianathan
et al., 2004), histone H1 (Mishra et al., 2010) and/or myristoylated
alanine-rich kinase C substrate (Theis et al., 2013). Although the
ability of tegaserod to interact with these molecules is yet un-
known, it can plausibly be expected that, given the structural and
functional similarity of tegaserod with oligomers within PSA,
tegaserod will subserve many interactions of PSA.
It is noteworthy that tegaserod leads to maximal neurite
extension in vitro at 1/10th and 1/100th of the doses required for
the peptide mimetic and colominic acid, respectively. Other in vitro
experiments with modiﬁed PSA derivatives used mM to mM PSA
concentrations and PSA of different chain lengths (Berski et al.,
2008; Haile et al., 2008). Although these results are not strictlyA) following femoral nerve injury and insertion of a conduit containing vehicle alone,
increase following injury, and a return toward pre-injury angles indicates recovery. (A)
ek recovery period. ***p < 0.0005 via one-way ANOVA with Tukey’s post-hoc test. (B)
by normalizing the recovery of individual animals to their pre-injury FBA, **p < 0.005,
Fig. 6. Evaluation of functional recovery via the protraction limb ratio (PLR) following femoral nerve injury. Pre-injury PLR of 1 is increased following injury as the injured limb
cannot extend to the same extent as the uninjured limb. A return to 1 indicates recovery of function. (A) PLR of mice that received vehicle, 250 nM tegaserod, or 2,500 nM tegaserod
measured over a 15-week recovery period. *p < 0.05 via one-way ANOVA with Tukey’s post-hoc test. (B) Recovery index (RI) of PLR of individual animals within each treatment
group after 15 weeks.
J. Bushman et al. / Neuropharmacology 79 (2014) 456e466 463comparable to the ones of the present study, they indicate that
concentrations of native PSA in the in the higher mM range are
needed for optimal effects.
In a previous study, the extent of regeneration induced by mM
concentrations of the PSA peptide mimetic in the same injury
model (Mehanna et al., 2009) was similar to that promoted by
250 nM tegaserod in the present study which showed that 250 nM
of tegaserod beneﬁcially acted in regeneration as indicated by
several parameters measured in vivo. The level of recovery was
superior or equivalent to that promoted by PSA and the PSA peptide
mimetic in this and other peripheral nervous system regeneration
paradigms (Gravvanis et al., 2007; Haastert-Talini et al., 2010;
Jungnickel et al., 2009, 2012; Marino et al., 2009; Masand et al.,
2012; Mehanna et al., 2009). While the proof-of-concept experi-
ments of the present study are encouraging, it will be important to
assess the ability of tegaserod to promote nerve repair in larger
peripheral nerve gaps or other paradigms of regeneration in acutely
and chronically injured mammalian nervous systems.Fig. 7. Mass of quadriceps muscle of mice after 15-week recovery period. (A) Images of
representative quadriceps muscles from the healthy and injured hind limbs of mice
following femoral nerve injury and insertion of a conduit containing vehicle or two
doses of tegaserod. (B) Quantiﬁcation of average quadriceps muscle masses of mice
that received vehicle, 250 nM tegaserod, or 2,500 nM tegaserod, and the average
muscle mass from the uninjured hind limbs. *p < 0.05 via Student’s t-test.The effects of PSA, the peptide mimetic and colominic acid on
neurite extension plateau at concentrations in the mM range while
higher doses of tegaserod in vitro show a reduced level of stimu-
lation and the highest doses were comparable to unstimulated
control values. It is not uncommon for drugs to have an optimal
dose range and exert undesirable effects if this dose range is
exceeded. It is interesting in this context that overall cell viability
was not reduced at higher doses; the reason for the function
reducing effects on neurite extension at higher concentrations is
presently unknown. It should be noted that the reduced average
values of locomotor recovery observed in vivo at 2500 nM con-
centrations could be due to a single animal in this group where no
axons were detected by histological analysis, thus raising the pos-
sibility that this dose mirrors the less beneﬁcial effects seen at
higher doses in vitro.
Like most agonists, tegaserod is not entirely speciﬁc for its
cognate receptor, the 5-HT4 receptor and stimulates, although less
efﬁciently, other serotonin receptors (Sanger, 2009; Smith et al.,
2008). Of these receptors, 5-HT2B has been reported in rat pe-
ripheral nerves and tegaserod’s pharmacological effect on human
5-HT2B is only 10% of that achieved via 5-HT4 receptor (Beattie et al.,
2004; Smith et al., 2008). The 5-HT2B receptor in rat peripheral
nerves is expressed by Schwann cells (Gaietta et al., 2003; Yoder
et al., 1997) and triggering this receptor leads to Ca2þ release
from Schwann cells in vitro (Yoder et al., 1996). How serotonin af-
fects Schwann cell process extension or peripheral nerve regener-
ation has not been investigated.
Expression of 5-HT4 receptor mRNA in rat DRG neurons has
been reported (Nicholson et al., 2003), but the functional impli-
cations of 5-HT4 actions in the PNS outside of the enteric nervous
system remain to be determined. Our data indicate that the 5-HT4
receptor agonists serotonin and cisapride fail to promote neurite
extension from DRG neurons, while tegaserod is effective and its
action is not reduced by the 5-HT4 receptor antagonist GR113808.
Despite these effects, it is unlikely that the improvements in
functional motor control and muscle mass noted in our studies
would be due to an effect of tegaserod on sensory axons. Sensory
axons lack the intrinsic capability of stimulating muscles and
those sensory axons that mistakenly reinervate into the motor
branch following nerve injury are removed in a process called
pruning (Brushart, 1993; Redett et al., 2005). However, while
tegaserod has been found to stimulate neurite extension in vitro
as PSA does via NCAM, we cannot rule out the possibility that
tegaserod may be acting through other PSA receptors or addi-
tional indirect pathways in vivo to promote peripheral nerve
regeneration.
Fig. 8. Histology of femoral nerves and quantiﬁcation of regenerated axons after a 15-
week recovery period. (AeC) 10 and 100 magniﬁcation images of regenerated
nerves from animals treated with (A) vehicle control, (B) 250 nM tegaserod, and (C)
2,500 nM tegaserod. (D) Dot plot shows the numbers of axons in the center of the
regenerated nerves and averages within groups. *p < 0.05 via Student’s t-test.
J. Bushman et al. / Neuropharmacology 79 (2014) 456e466464Current FDA-approved conduits for the repair of peripheral
nerves are reported to only be effective for gaps of 3 cm, and
regeneration is often suboptimal for these smaller gap sizes (Kehoe
et al., 2012). These in-market conduits provide mechanical and
directional support, but are not biologically inductive. Thus,
increasing the success of off-the-shelf conduits will depend upon
incorporation of biological cues to stimulate nerve regeneration.
Many studies over the last 40 years have investigated the potential
of a broad range of molecules and cells to improve peripheral nerve
regeneration in animal models with promising results. However,
only conduits that are biologically inert have entered the market.
Likely reasons for this are (a) the failure of the enhancing agent to
prove sufﬁcient beneﬁt in longer nerve gaps, (b) the expenseneeded for clinical trials and establishing good manufacturing
processes (GMP) for the enhancers, and (c) the time consuming and
costly regulatory approval pathway.
Tegaserod would be advantageous in these respects. The con-
centrations needed to promote nerve regeneration are orders of
magnitude lower than those administered for irritable bowel syn-
drome in humans: 2e12 mg/day or 0.025e0.15 mg/kg for an 80 kg
patient for a 4e6 week application time as opposed to 46 pg in a
single on-site dose in a 20 g mouse, comparable to 2  106 mg/kg,
for administration to an injured peripheral nerve. Application of
tegaserod at lower than clinically used concentrations could avoid
the need for replication of toxicological and pharmacological pro-
ﬁles. In the context of nerve regeneration, tegaserod would be
delivered in a single on-site dose, either encapsulated within a
scaffold as used in this report or preferably slowly released from a
biodegradable drug-eluting conduit. On-site delivery via the
conduit should also greatly minimize the likelihood of the very rare
adverse coronary effects reported for daily oral administration of
high doses of tegaserod (Busti et al., 2004; Schiller and Johnson,
2008). As a previously FDA approved drug with established GMP,
commercial translation may likewise be facilitated. Thus, tegaserod
has the potential to be repurposed for the application not only of
peripheral nerve repair, but hopefully also for amelioration of
central nervous system disabilities where PSA is likely to play an
important therapeutic role.5. Conclusions
Glycans, such as PSA, play an important role in nervous system
development, synaptic plasticity and regeneration following injury.
The application of small molecule compounds that mimic the
beneﬁcial activity of glycans, such as also the HNK-1 carbohydrate,
for nervous system repair may prove to be valuable additions to
treatments that rely on other classes of compounds. Also, evalu-
ating approved drugs for alternate mechanisms of action may open
novel approaches to pharmacological actions.Conﬂict of interest statement
The authors declare no conﬂicts of interest regarding this work.
The opinions and assertions contained herein are the private views
of the authors and are not to be construed as ofﬁcial or as reﬂecting
the views of the U.S. Army or the U.S. Department of Defense. This
paper has been approved for public release with unlimited
distribution.Acknowledgments
The authors are very grateful to Dr. Rita Gerady-Schahn for
donation of the antibody 735, Markus Wolf and Ute Bork for
excellent technical assistance, Dr. Philip Gribbon for help with
screening, and Dr. David Shreiber for helpful discussions. Dr. Jian
Chen, Dr. Ijaz Ahmed, Mr. Mikel Ehntholt, Ms. Diane Kim and Ms.
Sruti Golthi provided invaluable assistance with animal surgery,
videotracking and handling of animals, as well as histology. Melitta
Schachner is New Jersey Professor of Spinal Cord Research.References
Angata, K., Fukuda, M., 2010. Roles of polysialic acid in migration and differentiation
of neural stem cells. Methods Enzymol. 479, 25e36.
Beattie, D.T., Smith, J.A., Marquess, D., Vickery, R.G., Armstrong, S.R., Pulido-Rios, T.,
McCullough, J.L., Sandlund, C., Richardson, C., Mai, N., Humphrey, P.P., 2004. The
5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist
in vitro and in vivo. Br. J. Pharmacol. 143, 549e560.
J. Bushman et al. / Neuropharmacology 79 (2014) 456e466 465Berski, S., van Bergeijk, J., Schwarzer, D., Stark, Y., Kasper, C., Scheper, T., Grothe, C.,
Gerardy-Schahn, R., Kirschning, A., Drager, G., 2008. Synthesis and biological
evaluation of a polysialic acid-based hydrogel as enzymatically degradable
scaffold material for tissue engineering. Biomacromolecules 9, 2353e2359.
Brushart, T.M., 1993. Motor axons preferentially reinnervate motor pathways.
J. Neurosci. 13, 2730e2738.
Busti, A.J., Murillo Jr., J.R., Cryer, B., 2004. Tegaserod-induced myocardial infarction:
case report and hypothesis. Pharmacotherapy 24, 526e531.
Durbec, P., Cremer, H., 2001. Revisiting the function of PSA-NCAM in the nervous
system. Mol. Neurobiol. 24, 53e64.
El Maarouf, A., Petridis, A.K., Rutishauser, U., 2006. Use of polysialic acid in repair of
the central nervous system. Proc. Natl. Acad. Sci. U. S. A. 103, 16989e16994.
Evans, S.V., Sigurskjold, B.W., Jennings, H.J., Brisson, J.R., To, R., Tse, W.C., Altman, E.,
Frosch, M., Weisgerber, C., Kratzin, H.D., 1995. Evidence for the extended helical
nature of polysaccharide epitopes. The 2.8 A resolution structure and thermo-
dynamics of ligand binding of an antigen binding fragment speciﬁc for alpha-
(2–>8)-polysialic acid. Biochemistry 34, 6737e6744.
Finne, J., Finne, U., Deagostini-Bazin, H., Goridis, C., 1983. Occurrence of alpha 2-8
linked polysialosyl units in a neural cell adhesion molecule. Biochem. Biophys.
Res. Commun. 112, 482e487.
Franceschini, I., Vitry, S., Padilla, F., Casanova, P., Nam Tham, T., Fukuda, M.,
Rougon, G., Durbec, P., Dubois-Dalcq, M., 2004. Migrating and myelinating
potential of neural precursors engineered to overexpress PSA-NCAM. Mol. Cell.
Neurosci. 27, 151e162.
Franz, C.K., Rutishauser, U., Rafuse, V.F., 2005. Polysialylated neural cell adhesion
molecule is necessary for selective targeting of regenerating motor neurons.
J. Neurosci. 25, 2081e2091.
Friesner, R.A., Banks, J.L., Murphy, R.B., Halgren, T.A., Klicic, J.J., Mainz, D.T.,
Repasky, M.P., Knoll, E.H., Shelley, M., Perry, J.K., Shaw, D.E., Francis, P.,
Shenkin, P.S., 2004. Glide: a new approach for rapid, accurate docking and
scoring. 1. Method and assessment of docking accuracy. J. Med. Chem. 47, 1739e
1749.
Frosch, M., Gorgen, I., Boulnois, G.J., Timmis, K.N., Bitter-Suermann, D., 1985. NZB
mouse system for production of monoclonal antibodies to weak bacterial an-
tigens: isolation of an IgG antibody to the polysaccharide capsules of Escherichia
coli K1 and group B Meningococci. Proc. Natl. Acad. Sci. U. S. A. 82, 1194e1198.
Gaietta, G.M., Yoder, E.J., Deerinck, T., Kinder, K., Hanono, A., Han, A., Wu, C.,
Ellisman, M.H., 2003. 5-HT2A receptors in rat sciatic nerves and Schwann cell
cultures. J. Neurocytol. 32, 373e380.
Gale, J.D., Grossman, C.J., Whitehead, J.W., Oxford, A.W., Bunce, K.T., Humphrey, P.P.,
1994. GR113808: a novel, selective antagonist with high afﬁnity at the 5-HT4
receptor. Br. J. Pharmacol. 111, 332e338.
Gravvanis, A.I., Lavdas, A.A., Papalois, A., Tsoutsos, D.A., Matsas, R., 2007. The
beneﬁcial effect of genetically engineered Schwann cells with enhanced
motility in peripheral nerve regeneration: review. Acta Neurochir. Suppl. 100,
51e56.
Haastert-Talini, K., Schaper-Rinkel, J., Schmitte, R., Bastian, R., Muhlenhoff, M.,
Schwarzer, D., Draeger, G., Su, Y., Scheper, T., Gerardy-Schahn, R., Grothe, C.,
2010. In vivo evaluation of polysialic acid as part of tissue-engineered nerve
transplants. Tissue Eng. Part A 16, 3085e3098.
Haile, Y., Berski, S., Drager, G., Nobre, A., Stummeyer, K., Gerardy-Schahn, R.,
Grothe, C., 2008. The effect of modiﬁed polysialic acid based hydrogels on the
adhesion and viability of primary neurons and glial cells. Biomaterials 29,
1880e1891.
Hammond, M.S., Sims, C., Parameshwaran, K., Suppiramaniam, V., Schachner, M.,
Dityatev, A., 2006. Neural cell adhesion molecule-associated polysialic acid
inhibits NR2B-containing N-methyl-D-aspartate receptors and prevents
glutamate-induced cell death. J. Biol. Chem. 281, 34859e34869.
Irintchev, I., 2011. Potentials and limitations of peripheral nerve injury models in
rodents with particular reference to the femoral nerve. Ann. Anat. 193, 276e
285.
Irintchev, A., Simova, O., Eberhardt, K.A., Morellini, F., Schachner, M., 2005. Impacts
of lesion severity and tyrosine kinase receptor B deﬁciency on functional
outcome of femoral nerve injury assessed by a novel single-frame motion
analysis in mice. Eur. J. Neurosci. 22, 802e808.
Jungnickel, J., Bramer, C., Bronzlik, P., Lipokatic-Takacs, E., Weinhold, B., Gerardy-
Schahn, R., Grothe, C., 2009. Level and localization of polysialic acid is critical for
early peripheral nerve regeneration. Mol. Cell. Neurosci. 40, 374e381.
Jungnickel, J., Eckhardt, M., Haastert-Talini, K., Claus, P., Bronzlik, P., Lipokatic-
Takacs, E., Maier, H., Gieselmann, V., Grothe, C., 2012. Polysialyltransferase
overexpression in Schwann cells mediates different effects during peripheral
nerve regeneration. Glycobiology 22, 107e115.
Karlsson, R., Michaelsson, A., Mattsson, L., 1991. Kinetic analysis of monoclonal
antibodyeantigen interactions with a new biosensor based analytical system.
J. Immunol. Methods 145, 229e240.
Kehoe, S., Zhang, X.F., Boyd, D., 2012. FDA approved guidance conduits and wraps
for peripheral nerve injury: a review of materials and efﬁcacy. Injury 43 (5),
553e572.
Kleene, R., Yang, H., Kutsche, M., Schachner, M., 2001. The neural recognition
molecule L1 is a sialic acid-binding lectin for CD24, which induces promotion
and inhibition of neurite outgrowth. J. Biol. Chem. 276, 21656e21663.
Kochlamazashvili, G., Senkov, O., Grebenyuk, S., Robinson, C., Xiao, M.F.,
Stummeyer, K., Gerardy-Schahn, R., Engel, A.K., Feig, L., Semyanov, A.,
Suppiramaniam, V., Schachner, M., Dityatev, A., 2010. Neural cell adhesion
molecule-associated polysialic acid regulates synaptic plasticity and learning byrestraining the signaling through GluN2B-containing NMDA receptors.
J. Neurosci. 30, 4171e4183.
Kochlamazashvili, G., Bukalo, O., Senkov, O., Salmen, B., Gerardy-Schahn, R.,
Engel, A.K., Schachner, M., Dityatev, A., 2012. Restoration of synaptic plasticity
and learning in young and aged NCAM-deﬁcient mice by enhancing neuro-
transmission mediated GluN2A-containing NMDA receptors. J. Neurosci. 32,
2263e2275.
Liu, M., Geddis, M.S., Wen, Y., Setlik, W., Gershon, M.D., 2005. Expression and
function of 5-HT4 receptors in the mouse enteric nervous system. Am. J. Physiol.
Gastrointest. Liver Physiol. 289, G1148eG1163.
Liu, M.T., Kuan, Y.H., Wang, J., Hen, R., Gershon, M.D., 2009. 5-HT4 receptor-
mediated neuroprotection and neurogenesis in the enteric nervous system of
adult mice. J. Neurosci. 29, 9683e9699.
Loers, G., Chen, S., Grumet, M., Schachner, M., 2005. Signal transduction pathways
implicated in neural recognition molecule L1 triggered neuroprotection and
neuritogenesis. J. Neurochem. 92, 1463e1476.
Loers, G., Saini, V., Mishra, B., Papastefanaki, F., Lutz, D., Chaudhury, S., Ripoll, D.R.,
Wallqvist, A., Gul, S., Schachner, M., Kaur, G., 2013 Aug 20. Nonyloxytryptamine
mimics polysialic acid and modulates neuronal and glial functions in cell cul-
ture. J. Neurochem.. http://dx.doi.org/10.1111/jnc.12408 (Epub ahead of print).
Luo, J., Bo, X., Wu, D., Yeh, J., Richardson, P.M., Zhang, Y., 2011. Promoting survival,
migration, and integration of transplanted Schwann cells by over-expressing
polysialic acid. Glia 59, 424e434.
Marino, P., Norreel, J.C., Schachner, M., Rougon, G., Amoureux, M.C., 2009.
A polysialic acid mimetic peptide promotes functional recovery in a mouse
model of spinal cord injury. Exp. Neurol. 219, 163e174.
Martini, R., Schachner, M., Brushart, T.M., 1994. The L2/HNK-1 carbohydrate is
preferentially expressed by previously motor axon-associated Schwann cells in
reinnervated peripheral nerves. J. Neurosci. 14, 7180e7191.
Masand, S.N., Chen, J., Perron, I.J., Hammerling, B.C., Loers, G., Schachner, M.,
Shreiber, D.I., 2012. The effect of glycomimetic functionalized collagen on pe-
ripheral nerve repair. Biomaterials 33, 8353e8362.
Mehanna, A., Mishra, B., Kurschat, N., Schulze, C., Bian, S., Loers, G., Irintchev, A.,
Schachner, M., 2009. Polysialic acid glycomimetics promote myelination and
functional recovery after peripheral nerve injury in mice. Brain 132, 1449e1462.
Mehanna, A., Jakovcevski, I., Acar, A., Xiao, M., Loers, G., Rougon, G., Irintchev, A.,
Schachner, M., 2010. Polysialic acid glycomimetic promotes functional recovery
and plasticity after spinal cord injury in mice. Mol. Ther. 18, 34e43.
Mishra, B., von der Ohe, M., Schulze, C., Bian, S., Makhina, T., Loers, G., Kleene, R.,
Schachner, M., 2010. Functional role of the interaction between polysialic acid
and extracellular histone H1. J. Neurosci. 30, 12400e12413.
Muhlenhoff, M., Eckhardt, M., Bethe, A., Frosch, M., Gerardy-Schahn, R., 1996. Pol-
ysialylation of NCAM by a single enzyme. Curr. Biol. 6, 1188e1191.
Muller, D., Djebbara-Hannas, Z., Jourdain, P., Vutskits, L., Durbec, P., Rougon, G.,
Kiss, J.Z., 2000. Brain-derived neurotrophic factor restores long-term potenti-
ation in polysialic acid-neural cell adhesion molecule-deﬁcient hippocampus.
Proc. Natl. Acad. Sci. U. S. A. 97, 4315e4320.
Muller-Lissner, S.A., Fumagalli, I., Bardhan, K.D., Pace, F., Pecher, E., Nault, B.,
Ruegg, P., 2001. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symp-
toms in irritable bowel syndrome patients with abdominal pain, bloating and
constipation. Aliment. Pharmacol. Ther. 15, 1655e1666.
Nagai, T., Miyaichi, Y., Tomimori, T., Yamada, H., 1989. Inhibition of mouse liver
sialidase by plant ﬂavonoids. Biochem. Biophys. Res. Commun. 163, 25e31.
Nicholson, R., Small, J., Dixon, A.K., Spanswick, D., Lee, K., 2003. Serotonin receptor
mRNA expression in rat dorsal root ganglion neurons. Neurosci. Lett. 337, 119e
122.
Papastefanaki, F., Chen, J., Lavdas, A.A., Thomaidou, D., Schachner, M., Matsas, R.,
2007. Grafts of Schwann cells engineered to express PSA-NCAM promote
functional recovery after spinal cord injury. Brain 130, 2159e2174.
Petridis, A., Wedderkopp, H., Hugo, H., Mehdorn, M.H., 2009. Polysialic acid over-
expression in malignant astrocytomas. Acta Neurochir. 151, 601e604.
Phillips, R.K., Wallace, M.H., Lynch, P.M., Hawk, E., Gordon, G.B., Saunders, B.P.,
Wakabayashi, N., Shen, Y., Zimmerman, S., Godio, L., Rodrigues-Bigas, M.,
Su, L.K., Sherman, J., Kelloff, G., Levin, B., Steinbach, G., 2002. A randomised,
double blind, placebo controlled study of celecoxib, a selective cyclooxygenase
2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 50,
857e860.
Plane, J.M., Shen, Y., Pleasure, D.E., Deng, W., 2010. Prospects for minocycline
neuroprotection. Arch. Neurol. 67, 1442e1448.
Quigley, E.M.M., 2011. Cisapride: what can we learn from the rise and fall of a
prokinetic? J. Dig. Dis. 12, 147e156.
Redett, R., Jari, R., Crawford, T., Chen, Y.G., Rohde, C., Brushart, T.M., 2005. Peripheral
pathways regulate motoneuron collateral dynamics. J. Neurosci. 25, 9406e9412.
Roche, P.-H., Figarella-Branger, D., Daniel, L., Bianco, N., Pellet, W., Pellissier, J.-F. ß,
1997. Expression of cell adhesion molecules in normal nerves, chronic axonal
neuropathies and Schwann cell tumors. J. Neurol. Sci. 151, 127e133.
Rothstein, J.D., Patel, S., Regan, M.R., Haenggeli, C., Huang, Y.H., Bergles, D.E., Jin, L.,
Dykes Hoberg, M., Vidensky, S., Chung, D.S., Toan, S.V., Bruijn, L.I., Su, Z.Z.,
Gupta, P., Fisher, P.B., 2005. Beta-lactam antibiotics offer neuroprotection by
increasing glutamate transporter expression. Nature 433, 73e77.
Sanger, G.J., 2009. Translating 5-HT4 receptor pharmacology. Neuro-
gastroenterolMotil 21, 1235e1238.
Schiller, L.R., Johnson, D.A., 2008. Balancing drug risk and beneﬁt: toward reﬁning
the process of FDA decisions affecting patient care. Am. J. Gastroenterol. 103,
815e819.
J. Bushman et al. / Neuropharmacology 79 (2014) 456e466466Schulze, C., 2000. Analysing biomolecular interactions: the surface plasmon reso-
nance technique. In: Pandalai, S. (Ed.), Recent Research Developments in
Comparative Biochemistry and Physiology. Transworld Research Network, Tri-
vandrum, India, pp. 77e90.
Senkov, O., Sun, M., Weinhold, B., Gerardy-Schahn, R., Schachner, M., Dityatev, A.,
2006. Polysialylated neural cell adhesion molecule is involved in induction of
long-term potentiation and memory acquisition and consolidation in a fear-
conditioning paradigm. J. Neurosci. 26, 10888e109898.
Simova, O., Irintchev, A., Mehanna, A., Liu, J., Dihne, M., Bächle, D., Sewald, N.,
Loers, G., Schachner, M., 2006. Carbohydrate mimics promote functional re-
covery after peripheral nerve repair. Ann. Neurol. 60, 430e437.
Smith, J., Beattie, D., Marquess, D., Shaw, J.P., Vickery, R., Humphrey, P., 2008. The
in vitro pharmacological proﬁle of TD-5108, a selective 5-HT(4) receptor agonist
with high intrinsic activity. Naunyn-Schmiedeberg’s Arch. Pharmacol. 378,
125e137.
Storms, S.D., Rutishauser, U., 1998. A role for polysialic acid in neural cell adhesion
molecule heterophilic binding to proteoglycans. J. Biol. Chem. 273, 27124e27129.
Tanaka, F., Otake, Y., Nakagawa, T., Kawano, Y., Miyahara, R., Li, M., Yanagihara, K.,
Inui, K., Oyanagi, H., Yamada, T., Nakayama, J., Fujimoto, I., Ikenaka, K., Wada, H.,
2001. Prognostic signiﬁcance of polysialic acid expression in resected non-small
cell lung cancer. Cancer Res. 61, 1666e1670.
Theis, T., Mishra, B., von der Ohe, M., Loers, G., Blackshear, P.J., Schachner, M.,
Kleene, R., 2013. Functional role of the interaction between polysialic acid and
myristoylated alanine rich C kinase substrate. J. Biol. Chem. 288, 6726e6742.
Torregrossa, P., Buhl, L., Bancila, M., Durbec, P., Schafer, C., Schachner, M., Rougon, G.,
2004. Selection of poly-alpha 2,8-sialic acid mimotopes from a random phagepeptide library and analysis of their bioactivity. J. Biol. Chem. 279, 30707e
30714.
Vaithianathan, T., Matthias, K., Bahr, B., Schachner, M., Suppiramaniam, V.,
Dityatev, A., Steinhauser, C., 2004. Neural cell adhesion molecule-associated
polysialic acid potentiates alpha-amino-3-hydroxy-5-methylisoxazole-4-
propionic acid receptor currents. J. Biol. Chem. 279, 47975e47984.
Yang, P., Major, D., Rutishauser, U., 1994. Role of charge and hydration in effects of
polysialic acid on molecular interactions on and between cell membranes.
J. Biol. Chem. 269, 23039e23044.
Yoder, E.J., Tamir, H., Ellisman, M.H., 1996. 5-Hydroxytryptamine 2A receptors on
cultured rat Schwann cells. Glia 17, 15e27.
Yoder, E.J., Tamir, H., Ellisman, M.H., 1997. Serotonin receptors expressed by mye-
linating Schwann cells in rat sciatic nerve. Brain Res. 753, 299e308.
Zhang, Y., Zhang, X., Yeh, J., Richardson, P., Bo, X., 2007a. Engineered expression of
polysialic acid enhances Purkinje cell axonal regeneration in L1/GAP-43 double
transgenic mice. Eur. J. Neurosci. 25, 351e361.
Zhang, Y., Ghadiri-Sani, M., Zhang, X., Richardson, P.M., Yeh, J., Bo, X., 2007b.
Induced expression of polysialic acid in the spinal cord promotes regeneration
of sensory axons. Mol. Cell. Neurosci. 35, 109e119.
Zhang, Y., Zhang, X., Wu, D., Verhaagen, J., Richardson, P.M., Yeh, J., Bo, X., 2007c.
Lentiviral-mediated expression of polysialic acid in spinal cord and condition-
ing lesion promote regeneration of sensory axons into spinal cord. Mol. Ther. 15,
1796e1804.
Zilkha-Falb, R., Ziv, I., Nardi, N., Offen, D., Melamed, E., Barzilai, A., 1997.
Monoamine-induced apoptotic neuronal cell death. Cell. Mol. Neurobiol. 17,
101e118.
